How we work with industry
Genomics England works to realise the potential benefits for patients from the 100,000 Genomes Project as quickly as possible. We recognise that the rapid translation of ground-breaking research into routine medical treatments demands new levels of cooperation between researchers, healthcare professionals, government, the public and industry.
Industry is an important link in the chain. It is the biomedical, pharmaceutical and diagnostic industries that have taken pioneering research and turned it into the medical innovations − such as the X-ray machine, MRI scanner and penicillin – that we take for granted today. They will similarly be responsible for many of the advances in the genomic medicine of tomorrow.
We also know that close cooperation with industry can kick-start a thriving genomic healthcare sector in the UK. In helping to make this country the “go-to destination” for research and development investment, industry can help to create jobs, economic opportunity and prosperity. Industry is also helping Genomics England to identify the assets it is creating – and allow us to deliver a return on public investment.
The Discovery Forum
Genomics England works with industry through its Discovery Forum. Created in July 2017, the Forum builds on the work of the GENE Consortium. You can find out more about the legacy of the GENE Consortium for the 100,000 Genomes Project here.
Companies have come together within the Discovery Forum to work in a pre-competitive environment with access to a selection of whole genome sequences.
Genomics England also works with companies that specialise in data analysis, so that the 100,000 Genomes Project can benefit from cutting edge advances in handling Big Data.
The Discovery Forum is building on the GENE Consortium and is also accepting new members.
View Discovery Forum Members- Aeglea Biotherapeutics
- Alexion
- Alzheimer’s Society
- AMRC
- Angle PLC
- AstraZeneca
- BC Platforms
- Benevolent
- Berg
- Biogen
- Biomarin
- Bluebee
- Braincures
- Bristol-Myers Squibb
- Cambridge Cancer Genomics
- Cambridge Epigenetix
- Cambridgegene Limited
- Celmatix Inc
- ConcR
- Congenica
- Daiichi Sankyo
- Debiopharm International
- Deloitte Monitor
- Denali Therapeutics
- Diploid
- Eagle Genomics
- Edico Genome
- Epilepsy Society
- Foundation Medicine
- Freenome
- Genedata
- Genemo
- Genomics plc
- GSK
- Guardant Health
- Helomics
- Horizon Diagnostics
- Inivata
- Intellia therapeutics
- IQVIA (QuintilesIMS)
- Lantern Pharma
- Lifebit
- Mendelian
- Microsoft
- Mitsubishi bank
- MQ-MentalHealth
- My Personal Therapeutics
- Netramark
- NGM Biopharmaceuticals
- Novogene
- Octimet
- Orion
- Pacific Biosciences
- ParkinsonsUK
- Petagene
- Precision Therapeutics (previously Skyline Medical)
- Qiagen
- QuantumDx
- Randox Biosciences
- Roam Analytics
- Roche
- Rhythm Pharmaceuticals
- Seven Bridges
- Shire
- Spark Therapeutics
- Spiral Genetics
- Takeda
- TATA Consulting Services
- Thermo Fisher Scientific
- UCB
- Verge Genomics
- Wales Gene Park
- WPMC
The Forum promotes collaboration in – and access to – the UK genomics environment, utilising industry expertise to maximise patient benefit through the 100,000 Genomes Project. Ultimately, the Discovery Forum will help the 100,000 Genomes Project and its partners to turn research findings into treatments, diagnostics and benefits for patients as soon as possible.
We keep personal information about our Discovery Forum members. For information about how we collect and use personal information please see the Privacy Notice for Genomics England Discovery Forum Members here.
